Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2022-03-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司独立董事关于使用闲置募集资金暂时补充流动资金事项的独立意见
Capital/Financing Update Classification · 90% confidence The document is an independent opinion from independent directors regarding the use of idle raised funds to temporarily supplement working capital. It references compliance with regulatory rules and company governance but does not contain financial statements or detailed financial data. The document is short (577 characters) and appears to be a formal opinion or statement related to a financing or capital use decision. It is not a full financial report, audit, or earnings release. It is also not a report publication announcement or certification letter. The content aligns best with a Capital/Financing Update (CAP) as it discusses the use of raised funds and capital management.
2022-03-27 Chinese
中源协和细胞基因工程股份有限公司十届十六次临时董事会会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a company's board of directors meeting, including election of a new chairman and committee appointments. It does not contain financial statements or detailed financial data. It is a formal disclosure about board/management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or announcement of a report publication.
2022-03-27 Chinese
东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司使用闲置募集资金暂时补充流动资金之核查意见
Regulatory Filings
2022-03-27 Chinese
中源协和细胞基因工程股份有限公司关于使用闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle raised funds to temporarily supplement working capital. It details the background of the fundraising, the current status of the raised funds, the board and supervisory approvals, and opinions from independent directors and the sponsor institution. The document does not contain financial statements or detailed financial performance data but rather focuses on the company's capital usage plans and compliance with regulatory requirements. The length is 3526 characters, which is relatively short and the content is an announcement about the use of funds rather than a full financial report. Therefore, it fits best into the category of Capital/Financing Update (CAP).
2022-03-27 Chinese
中源协和细胞基因工程股份有限公司十届九次临时监事会会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a resolution passed by the company's supervisory board regarding the temporary use of idle raised funds to supplement working capital. It includes details about the meeting, voting results, and compliance with regulatory requirements. The document does not contain financial statements or detailed financial data but is an announcement of a corporate decision related to capital use. It is not a full financial report, audit, or earnings release. It fits best under Capital/Financing Update (CAP) as it concerns the use of raised funds and capital management.
2022-03-27 Chinese
中源协和细胞基因工程股份有限公司2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2022 first extraordinary general meeting of shareholders of the company. It includes details about the meeting date, attendance, voting results, and legal witness statements. There is no financial data or report content, only the official voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes rather than a full report or presentation.
2022-03-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.